130 results about "Post transplant" patented technology

A transport container and methods for preserving an organ at a target temperature. The transport container can maintain the organ at a temperature of 6-8⁰C for improved results after transplantation. The transport container can store the organ at a target temperature of determined based on characteristics of the organ and the donor. A processor can determine the target temperature for preservation of the organ. The transport container can contain cooling media that is colder near the bottom of the transport container and warmer near the top of the transport container to counter uneven cooling caused by gravity.

A transport container and methods for preserving a heart at a hypothermic temperature. The transport container can maintain the heart at a temperature of 6-8° C. for improved results after transplantation. The preservation of the heart within this range can improve transplantation outcomes.

The art does not provide systematic and reproducible methods to personalize dosing of multiple immunosuppressive medications after transplantation. This invention provides a method to systematize multi-drug immuno suppression management in tissue and organ transplantation using an artificial intelligence-based complex systems approach. In embodiments of this invention, immunosuppression drug dose, blood drug concentrations, donor-derived fraction of cell free DNA (dd-cfDNA %), and aspartate aminotransferase are used to indicate allograft status or a proxy for allograft status, to generate a phenotypic response surface to produce individual treatment modalities and dosages using empirically determined unique coefficients. This surface is used to calculate appropriate immunosuppression drug doses associated with the desired outcome for that patient. Embodiments of this disclosure are directed to identifying optimized combinations of inputs for the complex system of the immunosuppressed transplant patient in order to avoid transplant rejection while avoiding unnecessary toxicity and maintaining a robust enough immune response to fight infection.

The invention discloses a large-scale nursery stock transplanting method and system. The method comprises the following steps: S1, acquiring environment state parameters of a target nursery stock and environment state parameters of a target transplanting area; s2, detecting the growth distribution of the root system of the target nursery stock by adopting a multi-modal root system detection technology, and constructing a three-dimensional model of the root system distribution of the nursery stock; s3, determining an optimal root ball size and a cutting path based on a detection result in the step S2 and the morphological structure data of the nursery stock obtained in the step S1; s4, according to the cutting path determined in the step S3, accurately positioning and cutting the root ball of the target nursery stock, and binding the cut root ball; s5, according to the terrain where the target nursery stock is located and the weight of the nursery stock, the bound root ball is hoisted to a transportation tool through automatic hoisting equipment; s6, the seedlings transported to the target transplanting area are planted in the preset planting holes, and the planted seedlings are preliminarily fixed; and S7, performing post-transplantation maintenance and monitoring on the planted nursery stock.

A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and / or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.

Described herein are methods for treating antibody mediated rejection of transplanted organs using inhibitors of IL-6. In one embodiment, the IL-6 inhibitor is Tocilizumab and is administered simultaneously or sequentially with intravenous immunoglobulin (IVIG).

The invention discloses a method for separating, purifying and transplanting spermatogonial stem cells of lateolabrax japonicus, the spermatogonial stem cells of lateolabrax japonicus are separated and purified, marine fish larvae or freshwater fish larvae are used as receptor larvae, and then the spermatogonial stem cells of lateolabrax japonicus are transplanted to abdominal cavities of the receptor larvae. The spermatogonial stem cells obtained through separation are complete in number, structure and function and low in cell clustering rate. After the transplanted spermatogonial stem cells are subjected to fluorescence labeling, the migration and proliferation processes of donor germ cells can be observed in receptor fishes of marine fish fries or freshwater fish fries, so that the receptor fishes with the chimeric germline are obtained. According to the method, through xenotransplantation of the spermatogonial stem cells, a'belly borrowing reproduction 'breeding mode is provided for the marine fishes, a new way for gamete preservation and rapid propagation is provided for the marine fishes with the long reproductive cycle, and a new method and a new thought are provided for genetic improvement and germplasm resource preservation.

An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is described. Methods of generating same and using same are also described.

The invention relates to the technical field of cartilage construction, in particular to an injectable tissue engineering cartilage in-vitro construction method which comprises the following steps: S1, micro-ecological cartilage environment simulation design; s2, self-assembly of the stent and space-time guidance; and S3, constructing a reversible tissue-degradation platform. A tissue engineering system highly simulating a natural cartilage microenvironment is constructed through the technology of combining bionic design and dynamic regulation and control, the proliferation activity and functional differentiation efficiency of cartilage cells can be effectively improved, and meanwhile, by means of intelligent support design and a growth factor delivery system, the tissue engineering system can be applied to the field of cartilage tissue engineering. Accurate release of factors and cell navigation are realized; the dynamic repair technology is combined with the non-contact mechanical stimulation and immune regulation strategy, it is ensured that transplanted tissue can be continuously generated and fully integrated with host tissue, the problems of immunological rejection or insufficient stent degradation and the like are solved, the success rate and long-term stability of cartilage regeneration are remarkably improved, and the method has good clinical application prospects.

The invention relates to the field of medical examination, in particular to application of a substance for detecting an SSBP2-FLT3 fusion gene in preparation of a product for detecting human leukemia. Aiming at the fusion gene SSBP2-FLT3, a specific PCR primer is designed, PCR amplification and sequencing are performed after nucleic acid is extracted from a patient sample, and the specific translocation site of the fusion gene is detected, so that the method is the most accurate, convenient and economical method. According to the application, DNA fusion gene detection and RNA fusion gene detection are combined, and meanwhile, as a molecular marker, an important basis can be provided for selecting a treatment scheme for a patient, predicting a recurrence risk and evaluating prognosis, and the molecular marker has an irreplaceable important effect in aspects of hematopoietic stem cell transplantation curative effect evaluation, pretreatment scheme optimization and post-transplantation molecular recurrence monitoring.

The invention discloses application of sorafenib in maintenance treatment of acute myelogenous leukemia after transplantation, and relates to the technical field of medicines, and the key points of the technical scheme are as follows: it is found for the first time that secretion and killing functions of NK cells can be enhanced by using sorafenib for maintenance treatment after transplantation; sorafenib enhances communication between macrophages and NK cells by promoting secretion of macrophage proinflammatory factors, so that the function of NK cells is enhanced. The invention clarifies that sorafenib enhances the GVL effect of NK cells in a low tumor load environment, discusses the molecular mechanism of sorafenib for enhancing the NK cell function by promoting macrophage metabolism reprogramming, and provides a new thought for maintaining precision and optimization of treatment after transplantation.

Disclosed are novel strategies for the treatment of patients with Parkinson's disease and other secondary Parkinsonian disorders. Disclosed are DA neuronal cells that have been modified in vitro with a genetic insertion of GDNF. The GDNF coding sequence is inserted under the transcriptional control of a promotor such that secreted proteins are made and taken up by the endogenous cells after the administered engineered cells have matured to a Neuronal Mature Cell Type to promote survival of endogenous neurons. Also disclosed are DA neuronal cells that have been modified with a genetic insertion of GBA in vitro and are hemizygous null for SNCA. The GBA coding sequence is inserted under the transcriptional control of a ubiquitous promotor and the secreted proteins are made and taken up by the graft and endogenous cells immediately upon transplantation to promote long-term graft integrity.

The invention relates to an acute leukemia (ALL) high-throughput flow cytometry kit, and belongs to the field of leukemia detection.16 ALL cell antigens are added on the basis of an original 8-color flow cytometry, 24 antigens in the same cell can be detected at the same time, the detection precision of minimal residual focus (MRD) is greatly improved, and the detection sensitivity is improved. The ALL cells are divided into 12 developmental stages, so that immunological typing during primary diagnosis and immunophenotype variation after bone marrow transplantation and CAR-T cell treatment can be more accurately recognized, and the method has very important guiding significance on evaluation of treatment effects of patients and adjustment of treatment schemes.

A method for handling, treating, and storing a cornea is disclosed that enables vitrification and rewarming in air and / or liquid nitrogen vapor without causing significant cell loss, cell death, or dysfunction after transplantation, as compared to untreated control corneas. The method utilizes osmotic imbalance and extreme corneal shrinkage due to corneal dehydration, and enables avoidance of cryoprotectant toxicity, even when exposed to the peak (vitrifiable) concentration of cryoprotectant above 0 °C for an extended period of time or when washing the cryoprotectant without performing osmotic buffering. The corneal device enables ideal handling and storage and air cooling inside or outside the container used for storage.

The invention belongs to the technical field of medical equipment, and particularly discloses a reversible electroporation combined medical kit for organ transplantation and transfer and application of the reversible electroporation combined medical kit. According to the medical kit for organ transplantation, a novel electric pulse device is additionally designed on the basis of original design, a large amount of emergency response generated after organ transplantation can be remarkably reduced, and the survival rate of organs is increased. The novel electric pulse device is designed to be attached to the inner wall of the box body, the designed electric pulse electrode plate is attached to the buffer pad, the buffer pad is made of an insulating non-toxic heat preservation material, and organ preservation liquid is contained in the organ preservation bag. According to the medical kit for organ transplantation, the additional electrodes can be used for applying electric pulses to organs in the organ storage bag, medicine in the organ storage liquid is promoted to enter the organs, meanwhile, the optimal applied pulse intensity is confirmed in combination with cell experiments, the potential distribution condition is simulated and confirmed in combination with simulation software, and emergency reaction generated after perfusion can be reduced; therefore, normal organ functions are ensured, and the success rate of transplantation is improved.

The invention discloses a composite artificial cavity / membrane tissue and a preparation method thereof. The composite artificial cavity / membrane tissue is formed by compounding a synthetic high-molecular material and a natural high-molecular biological material, and the synthetic high-molecular material is selected from more than one of silicone, synthetic high-molecular hydrogel and an acrylic polymer. The natural polymer biological material is selected from more than one of an acellular matrix scaffold material, a non-acellular matrix and non-acellular collagen. The composite artificial cavity / membrane tissue provided by the invention has the advantages of good healing after transplantation, high biomechanical strength, low immunogenicity, smooth surface and the like.

The embodiment of the invention provides a pancreas islet differentiation method and equipment for microencapsulated induced pluripotent stem cells, and relates to the field of stem cell differentiation. In order to solve the problems of low differentiation efficiency, low insulin secretion function and immunological rejection after transplantation of the two-dimensional cultured iPSC, a method for inducing the iPSC into the islet cells under a three-dimensional condition is constructed, the differentiation efficiency and the functions of the islet cells are improved, immune isolation transplantation can be directly performed after differentiation, and meanwhile, new equipment is constructed. The structure is beneficial to improving the mass transfer efficiency in the induction process, and large-scale and accurate condition control can be realized. The preparation method comprises the following steps: S1, mixing iPSC with a sodium alginate solution to form calcium alginate microspheres containing the iPSC; s2, culturing the iPSC in the calcium alginate microspheres obtained in the step S1 into a cell cluster; and S3, performing stage induced differentiation on the cell cluster obtained in the step S2 to obtain the endocrine cell cluster.

Provided are a detection reagent for acute graft-versus-host disease (aGVHD) and the use of the percentage of CD38+HLA−DR+CD8+ T cell as a biomarker for aGVHD. The present application has unexpectedly found that a proportion of the CD38+HLA−DR+CD8+ T cell in peripheral blood of a patient with aGVHD is significantly greater than that in peripheral blood of a healthy donor and a patient without aGVHD after transplantation. The receiver operating characteristic (ROC) curve analysis shows that the CD38+HLA−DR+CD8+ T cell has an area under the ROC curve (AUC) of 0.84, with a sensitivity of 80.8%, and a specificity of 75.0% when used in early diagnosis of aGVHD. Results indicate that the CD38+HLA−DR+CD8+ T cell is a marker for early diagnosis of aGVHD with a prominent diagnostic effect. The marker can guide the clinical medication.

The invention provides application of circRNA 3254 in preparation of a preparation or a medicine for preventing early apoptosis of transplanted islet cells, belongs to the technical field of islet transplantation, and aims to solve the important problems of relieving the early transplanted islet apoptosis, improving the transplanted islet function and prolonging the time of completely separating from insulin after transplantation in the current islet transplantation field. A circRNA sequencing result finds that circRNA participates in a process of improving the curative effect of transplanted pancreas islet by bone marrow mesenchymal stem cells (BMSCs) for the first time, and circRNA 3254 which is not reported in literatures is screened as a research target. The specific regulation effect of circRNA 3254 on the apoptosis condition of the early transplanted pancreas islet is verified in in-vivo and in-vitro models for the first time, and a mechanism network for improving the survival rate of the transplanted pancreas islet by the BMSCs is further improved. The specific regulation effect of circRNA 3254 on the apoptosis condition of the early transplanted pancreas islet is verified in in-vivo and in-vitro models for the first time, and a mechanism network for improving the survival rate of the transplanted pancreas islet by the BMSCs is further improved.

A three-dimensional oxygen-generating bioscaffold capable of supplying cells with a continuous, controlled, and steady source of oxygen and methods of using such an oxygengenerating bioscaffold to prevent hypoxia-induced damage to cells following transplantation are disclosed. In particular, a collagen-based cryogel bioscaffold having calcium peroxide (CPO) incorporated into its matrix is provided, wherein the CPO produces oxygen upon exposure to water. The collagen-based cryogel is designed with a plurality of macropores capable of encapsulating therapeutic cells for cellular therapy. Methods of producing oxygen-generating bioscaffolds and tissue grafts comprising therapeutic cells contained in such oxygen-generating bioscaffolds as well as their use in cellular therapy are also disclosed.

The invention discloses a mesenchymal stem cell preparation and application thereof, and belongs to the technical field of cell biology. The mesenchymal stem cell preparation is a mesenchymal stem cell pretreated by a combined drug of ziyuglycoside II and shikonin. Through drug pretreatment, the antioxidant capacity of the mesenchymal stem cells is synergistically enhanced, the survival rate of the cells after transplantation is enhanced, the treatment effect of the cells on the NAFLD hepatocytes is remarkably enhanced, and lipid accumulation in the hepatocytes is effectively reduced. Therefore, the invention provides a novel method for enhancing the treatment capacity of the mesenchymal stem cells NAFLD, the method is suitable for bone marrow and umbilical cord mesenchymal stem cells, and an efficient and reliable preparation and an optimization scheme are provided for clinical stem cell treatment of the NAFLD.

The present invention relates to means and methods for in vitro fertilisation, particularly to means and methods for frozen embryo transfer which comprise the use of a composition comprising an effective amount of estetrol component. The composition is intended for use prior, during and / or after embryo transfer. The use of the composition in a frozen embryo transfer fertility treatment results in favourable effects when compared to compositions used in the art to support frozen embryo transfer fertility treatments.

The invention discloses injectable hierarchical structure composite hydrogel for pancreas islet transplantation and a preparation method of the injectable hierarchical structure composite hydrogel, and belongs to the technical field of biomedical engineering. The preparation method comprises the following steps: introducing bubbles into an inner phase tube in a microfluidic device, introducing a hydrogel cell pre-polymerization solution into an outer phase tube, uniformly distributing the bubbles in the hydrogel cell pre-polymerization solution, then mixing with an ionic crosslinking aqueous phase solution, irradiating with blue light to obtain bubble-loaded hydrogel microfibers, and obtaining a pancreas islet-loaded short fiber stent after the bubbles are broken; mixing the oxidized sodium alginate solution with the carboxymethyl chitosan solution, and wrapping the angiogenesis promoting component to obtain a self-healing hydrogel matrix; and mixing the short fiber scaffold with the self-healing hydrogel matrix to obtain the injectable hierarchical structure composite hydrogel. The composite hydrogel has good biocompatibility, oxidation resistance and immune isolation effect, meanwhile, the hierarchical structure promotes formation of external vascularization, and long-term survival and function maintenance of transplanted plants after pancreas islet transplantation are facilitated.

The invention discloses a method for improving the normal fertilization rate of an in-vitro ICSI embryo of a dairy cow and reducing the abortion rate, which comprises the following steps: preparing an ICSI egg from X-sex controlled sperm and an oocyte which is cultured by a mature oocyte and is used as a donor by adopting a microinjection mode, the ICSI eggs are incubated in an oocyte maturation culture solution (OM) for 3-5 h and then transferred to ETH to be activated for 4-6 min so as to promote normal fertilization of the ICSI eggs, then embryo culture is conducted, and then sexual control embryos are obtained; the ETH refers to an oocyte maturation culture solution containing 6 to 8 percent of ethanol. The normal fertilization rate of the ICSI embryos produced by the method is remarkably improved, and the early abortion rate is remarkably reduced in inspection after transplantation.

Nanoparticles, methods, and kits are provided for supplying nutrients and other therapeutic agents to transplanted cells. Nutrient deprivation is a significant factor which contributes to poor outcome of many cell transplants because cells receive insufficient nutrients until they are able to establish a functional microcirculation to support their metabolic and physiological needs after transplantation. Nanoparticles are provided for use in supplying nutrients and other therapeutic agents to transplanted cells to improve cell survival. Such nanoparticles can be used to supply nutrients and other factors to transplanted cells until the transplanted cells are able to develop a new microcirculation.

The invention relates to the technical field of greening transplanting, and discloses a road greening disc transplanting and maintaining all-in-one machine based on a soil moisturizing structure, the road greening disc transplanting and maintaining all-in-one machine comprises a supporting frame, a mounting frame and a base plate, the mounting frame and the base plate are arranged on the supporting frame, a transplanting mechanism is arranged between the mounting frame and the base plate, an auxiliary assembly is arranged on the base plate, and the auxiliary assembly comprises a maintaining part and a moisturizing part. In the working process, maintenance and moisture preservation work of transplanted green plants is achieved. The road greening disc transplanting and maintaining all-in-one machine based on the soil moisturizing structure can effectively solve the problems that in the prior art, when facing a large-scale green belt reconstruction project, the whole process depends on manual digging and carrying, a large amount of manpower needs to be consumed, meanwhile, due to the fact that the efficiency is low, the whole transplanting period is remarkably prolonged, and some small green plants are difficult to transplant in the transplanting process. In the prior art, the root system is exposed in the air for a long time, and physiological damage is easily caused by excessive water loss, so that the transplanted green plant is directly poor in growth.

This invention discloses a co-culture immune isolation device after cell transplantation, belonging to the technical field of cell culture devices. The device includes a culture plate with several first cavities inside and placement slots outside the first cavities. A cover plate is provided above the culture plate, and several second cavities are provided on the cover plate. A sealing ring is provided on the outside of the second cavities, and a liquid inlet mechanism is provided inside the cover plate, connected to the second cavities. This invention uses the above-mentioned co-culture immune isolation device after cell transplantation to achieve co-culture of multiple cells by setting multiple independent first cavities, preventing cell migration or direct contact and avoiding immune rejection. The protective cover and liquid inlet mechanism achieve closed-loop automatic liquid inlet, continuously diffusing signal molecules into the first cavities to maintain co-culture homeostasis and achieve co-culture of multiple cells.

The present invention provides a cell composition for treating detrusor underactivity and a method for preparing the same. The cell composition comprises a cell spheroid formed by seeding a plurality of mesenchymal stem cells in a culture device comprising a plurality of culture wells, wherein each of the culture wells has a surface coated with a low-protein-adhesion layer, and culturing the cells under the conditions to induce spheroid formation. Through the cell composition of the present invention, three-dimensional structured cell spheroids are formed to promote intercellular interactions and physiological function expression, thereby enhancing cell survival rates and functional performance after transplantation. In particular, the cell composition effectively facilitates the repair and restoration of contractile function of bladder muscle tissue, thereby improving the clinical symptoms associated with detrusor underactivity.

The invention belongs to the field of biological medicine, and particularly discloses a culture method of domesticated mesenchymal stem cells (MSCs), which comprises the following steps: separating plasma and platelet lysis buffer from autologous peripheral blood, and obtaining CTL and Treg through magnetic bead sorting; the method comprises the following steps: sequentially co-culturing umbilical cord MSCs for three generations: co-culturing the P1 generation and CTL in a culture medium containing 30% of alpha MEM, 68% of DMEM / F12, 1% of autologous plasma and 1% of platelet lysis buffer, and adding 0.1-1 [mu] M of resveratrol and 10-50 [mu] M of spermidine; co-culturing P2 and Treg in a culture medium containing 50% of alpha MEM, 48% of DMEM / F12, 1% of autologous plasma and 1% of platelet lysis buffer; the P3 generation is cultured and harvested in 90% of alpha MEM, 5% of DMEM / F12 and 5% of PRP. The obtained MSCs surface marker is CD105 < + > / CD90 < + > / CD73 < + > / CD45 <-> / CD34 <-> / HLA-DR <->, the expression quantity of CD24 is low (CD24low), the expression quantity of CD47 is high (CD47high), the expression quantity of PD-L1 is high (PD-L1 high), the IDO activity is larger than or equal to 25 U / mg, the retention rate of the lung after vein transplantation is smaller than or equal to 12%, and the survival period is larger than or equal to 28 days. The cell is suitable for treating ARDS or hepatic fibrosis.

To provide novel nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof.SOLUTION: The present invention provides a compound represented by the general formula [I] in the figure, where each symbol is as defined herein, or a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutical use of the same in treating organ transplant rejection, graft versus host reaction after transplantation, autoimmune disease, allergic disease and chronic myeloproliferative disease.SELECTED DRAWING: None